Fig. 2From: A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver diseaseAssociation between baseline HOMA-IR and AST, rho = 0.489, p < 0.01, 95% confidence intervalBack to article page